Federal Register / Vol. 74, No. 40 / Tuesday, March 3, 2009 / Notices 9253 

Craniofacial Research, Oral and 

Pharyngeal Cancer Branch, is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize this technology. Please 

contact David W. Bradley, PhD at 

bradleyda@nidcr.nih.gov for more 

information. 

Use of Tetracyclines as Anti-Cancer 

Agents 

Description of Technology: The 

invention describes compositions of 

tetracycline compounds and their 

derivatives as having anti-cancer 

activity, as well as methods of treating 

cancer. Tetracyclines are commonly 

used as antibiotics; however, testing of 

these compounds in a high throughput 

screening system revealed certain 

derivatives to be potent inhibitors of 

tyrosyl-DNA-phosphodiesterase (Tdp1). 

Camptothecins are effective 

Topoisomerase I (Top1) inhibitors, and 

two derivatives (Topotecan® and 

Camptosar®) are currently approved for 

treatment of ovarian and colorectal 

cancer. Camptothecins damage DNA by 

trapping covalent complexes between 

the Top1 catalytic tyrosine and the 3=- 

end of the broken DNA. Tdp1 repairs 

Top1-DNA covalent complexes by 

hydrolyzing the tyrosyl-DNA bond. This 

can reduce the effectiveness of 

camptothecins as anti-cancer agents. In 

addition, Tdp1 repairs free-radicalmediated DNA breaks. 

As disclosed in the instant 

technology, tetracyclines have the 

potential to enhance the anti-neoplastic 

activity of Top1 inhibitors by reducing 

repair of Top1-DNA lesions through 

inhibition of Tdp1. Inhibition of Tdp1 

may also reduce repair of DNA breaks 

and increase the rate of apoptosis in 

cancer cells, making them potential 

anti-cancer agents on their own. 

Development Status: Pre-clinical 

stage. 

Inventors: Yves Pommier, Christophe 

Marchand, Laurent Thibaut (NCI). 

Publications: 1. Z Liao et al. 

Inhibition of human tyrosyl-DNA 

phosphodiesterase (Tdp1) by 

aminoglycoside antibiotics and 

ribosome inhibitors. Mol Pharmacol. 

2006 Jul;70(1):366–372. 

2. Y Pommier. Camptothecins and 

topoisomerase I: A foot in the door. 

Targeting the genome beyond 

topoisomerase I with camptothecins and 

novel anticancer drugs: Importance of 

DNA replication, repair and cell cycle 

checkpoints. Curr Med Chem 

Anticancer Agents. 2004 Sep;4(5):429– 

434. Review. 

3. Y Pommier et al. Repair of and 

checkpoint response to topoisomerase I 

mediated DNA damage. Mutat Res. 2003 

Nov 27;532(1–2):173–203. Review. 

Patent Status: U.S. Provisional 

Application No. 60/786,746 filed 27 Mar 

2006 (HHS Reference No. E–097–2006/ 

0–US–01). 

International Application No. PCT/ 

US2007/007724 filed 27 Mar 2007 (HHS 

Reference No. E–097–2006/0–PCT–02). 

U.S. Patent Application No. 12/ 

241,011 filed 29 Sep 2008 (HHS 

Reference No. E–097–2006/1–US–01). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Betty Tong, PhD; 

301–594–6565; tongb@mail.nih.gov. 

Collaborative Research Opportunity: 

The Laboratory of Molecular 

Pharmacology at the National Cancer 

Institute is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize tetracycline derivatives, 

particularly optimizing them for 

therapeutic use. Please contact John D. 

Hewes, PhD at 301–435–3121 or 

hewesj@mail.nih.gov for more 

information. 

Glutathione S-transferase Clones for 

Members of the Ubiquitin-Dependent 

Protein Degradation Pathway 

Description of Technology: Scientists 

at the National Institutes of Health have 

developed cDNA for glutathione Stransferase (GST) clones for the 

following factors: Nedd4, XIAP, 

UBCH5B, and CBL–B. These proteins 

are involved in the ubiquitin-dependent 

pathway of protein degradation in cells, 

the major cellular system for protein 

degradation. The ubiquitin-proteosome 

pathway regulates several cancer 

regulated proteins. Defects in this 

pathway can lead to cancer 

development. The GST clones can be 

used to produce corresponding GST 

fusion proteins in order to isolate each 

protein from the pathway for further 

analysis. These constructs can also be 

incorporated into assays/kits to detect 

proteins in the ubiquitin-dependent 

pathway. 

Applications: Research tools for 

detection and isolation of ubiquitindependent pathway members in order to 

understand the pathway defects that 

lead to cancer and develop preventions 

and treatments to overcome these 

defects. 

Research tools for generating fusion 

proteins of Nedd4, XIAP, UBCH5B, and 

CBL–B to further analyze their functions 

in vivo and in vitro. 

Controls for screening inhibitors of 

the ubiquitin-dependent pathway in 

order to better understand the different 

mechanisms of ubiquitin-dependent 

protein degradation. 

Inventors: Allan M. Weissman et al. 

(NCI). 

Patent Status: HHS Reference No. E– 

245–2003/0—Research Tool. Patent 

protection is not being pursued for this 

technology. 

Licensing Status: Available for 

licensing under a Biological Materials 

License Agreement. 

Licensing Contact: Samuel E. Bish, 

Ph.D.; 301–435–5282; 

bishse@mail.nih.gov. 

Dated: February 24, 2009. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E9–4477 Filed 3–2–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Microbiology, 

Infectious Diseases and AIDS Initial Review 

Group; Acquired Immunodeficiency 

Syndrome Research Review Committee. 

Date: March 30–31, 2009. 

Time: 8 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Washington/Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Contact Person: Erica L. Brown, PhD, 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institutes of Health/NIAID, 6700B 

Rockledge Drive, MSC 7616, Bethesda, MD 

20892–7616, 301–451–2639, 

ebrown@niaid.nih.gov. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Pandemic Flu. 

Date: April 1, 2009. 

mstockstill on PROD1PC66 with NOTICES

9254 Federal Register / Vol. 74, No. 40 / Tuesday, March 3, 2009 / Notices 

Time: 9 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6700B 

Rockledge Drive, Bethesda, MD 20817, 

(Telephone Conference Call). 

Contact Person: Clayton C. Huntley, PhD, 

Scientific Review Officer, Scientific Review 

Program, National Institutes of Health/NIAID, 

Room 3124, 6700B Rockledge Drive, MSC 

7616, Bethesda, MD 20892–7616, 301–451– 

2570, chuntley@niaid.nih.gov. 

(Catalogue of Federal Domestic 

Assistance Program Nos. 93.855, 

Allergy, Immunology, and 

Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, 

HHS) 

Dated: February 24, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–4411 Filed 3–2–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Eye Institute 

Special Emphasis Panel; Research Grant 

Applications. 

Date: March 26, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites at the Chevy Chase 

Pavilion, 4300 Military Road, NW., 

Washington, DC 20015. 

Contact Person: Houmam H Araj, PhD, 

Scientific Review Administrator, Division of 

Extramural Research, National Eye Institute, 

NIH, 5635 Fishers Lane, Suite 1300, 

Bethesda, MD 20892–9602, 301–451–2020, 

ha50c@nih.gov. 

Name of Committee: National Eye Institute 

Special Emphasis Panel; NEI Mentored 

Career Development Grant Applications (K). 

Date: March 31, 2009. 

Time: 12 p.m. to 2:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 5635 

Fishers Lane, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Anne E Schaffner, PhD, 

Scientific Review Officer, Division of 

Extramural Research, National Eye Institute, 

5635 Fishers Lane, Suite 1300, MSC 9300, 

Bethesda, MD 20892–9300, (301) 451–2020, 

aes@nei.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.867, Vision Research, 

National Institutes of Health, HHS) 

Dated: February 23, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–4286 Filed 3–2–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

Board of Scientific Counselors, NIA. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended 

for the review, discussion, and 

evaluation of individual intramural 

programs and projects conducted by the 

National Institute on Aging, including 

consideration of personnel 

qualifications and performance, and the 

competence of individual investigators, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Board of Scientific 

Counselors, NIA. 

Date: May 12–13, 2009. 

Time: May 12, 2009, 8 a.m to 4 p.m. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individual investigators. 

Place: National Institute on Aging, 

Biomedical Research Center, 251 Bayview 

Blvd., 3rd Floor Conference Room, Baltimore, 

MD 21224. 

Time: May 13, 2009, 8 a.m to 1:50 p.m. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individual investigators. 

Place: National Institute on Aging, 

Biomedical Research Center, 251 Bayview 

Blvd., 3rd Floor Conference Room, Baltimore, 

MD 21224. 

Contact Person: Dan L. Longo, MD, 

Scientific Director, National Institute of 

Aging, Gerontology Research Center, 

National Institutes of Health, 5600 Nathan 

Shock Drive, Baltimore, MD 21224–6825. 

410–558–8110, dl14q@nia.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.866, Aging Research, 

National Institutes of Health, HHS) 

Dated: February 23, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–4265 Filed 3–2–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

Center for AIDS Intervention Research Core 

Support. 

Date: March 20, 2009. 

Time: 1 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Enid Light, PhD, Scientific 

Review Officer, Division of Extramural 

Activities, National Institute of Mental 

Health, NIH, Neuroscience Center, 6001 

Executive Boulevard, Room 6132, MSC 9608, 

Bethesda, MD 20852–9608, 301–443–0322, 

elight@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.242, Mental Health Research 

Grants; 93.281, Scientist Development 

Award, Scientist Development Award for 

Clinicians, and Research Scientist Award; 

93.282, Mental Health National Research 

Service Awards for Research Training, 

National Institutes of Health, HHS) 

mstockstill on PROD1PC66 with NOTICES